FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 1, 2013, Pages 34-43

  Graf, Nicolas ^a,d   Herrmann, Ken ^a   Numberger, Barbara ^a   Zwisler, Daniela ^a   Aichler, Michaela ^a   Feuchtinger, Annette ^a   Schuster, Tibor ^b   Wester, Hans Jürgen ^a   Senekowitsch Schmidtke, Reingard ^a   Peschel, Christian ^a   Schwaiger, Markus ^a   Keller, Ulrich ^a   Dechow, Tobias ^a   Buck, Andreas K ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d Abteilung Hämatologie und Onkologie   (Germany)

Author keywords

Dose dependency; FDG PET; FLT PET; Lymphoma; Therapy monitoring

Indexed keywords

3' FLUOROTHYMIDINE F 18; CASPASE 3; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; TETRAZOLIUM; THYMIDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; ANTINEOPLASTIC ANTIBIOTIC; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; GLUCOSE METABOLISM; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOMA CELL; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT; ANIMAL; CANCER STAGING; CANCER TRANSPLANTATION; CELL PROLIFERATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; HUMAN; MOUSE MUTANT; SCINTISCANNING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CASPASE 3; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MICE, SCID; NEOPLASM STAGING; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84875750045     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2255-0     Document Type: Article

References (42)

1. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
2. Surbone A, Longo DL, DeVita Jr VT, Ihde DC, Duffey PL, et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol. 1988;6:1832-7.
3. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-8.
4. Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, et al. FDG-PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics. 2005;25:191-207.
5. van Waarde A, Cobben DC, Suurmeijer AJ, Maas B, Vaalburg W, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004;45:695-700.
6. Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med. 1998;39:1757-62.
7. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-6.
8. Barthel H, Perumal M, Latigo J, He Q, Brady F, et al. The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging. 2005;32:257-63.
9. Eriksson S, Arnér E, Spasokoukotskaja T, Wang L, Karlsson A, et al. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. Adv Enzyme Regul. 1994;34:13-25.
10. Seitz U, Wagner M, Neumaier B, Wawra E, Glatting G, et al. Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[(18)F]fluoro- 3′-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging. 2002;29:1174-81.
11. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-7.
12. Lu L, Samuelsson L, Bergstrom M, Sato K, Fasth KJ, et al. Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. J Nucl Med. 2002;43:1688-98.
13. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005;46:945-52.
14. Cobben DC, Elsinga PH, Suurmeijer AJ, Vaalburg W, Maas B, et al. Detection and grading of soft tissue sarcomas of the extremities with (18)F-3′-fluoro-3′-deoxy-L-thymidine. Clin Cancer Res. 2004;10:1685-90.
15. Smyczek-Gargya B, Fersis N, Dittmann H, Vogel U, Reischl G, et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2004;31:720-4.
16. Wagner M, Seitz U, Buck A, Neumaier B, Schultheiss S, et al. 3′-[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res. 2003;63:2681-7.
17. Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66:11055-61.
18. Herrmann K, Wieder HA, Buck AK, Schöffel M, Krause BJ, et al. Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552-8.
19. Graf N, Herrmann K, den Hollander J, Fend F, Schuster T, et al. Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol Imaging Biol. 2008;10(6):349-55.
20. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica. 2000;85(6):613-8.
21. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13(9):1356-63.
22. Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28(11):1896- 903.
23. Han HS, Escalón MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol. 2009;20(2):309-18.
24. Brepoels L, De Saint-Hubert M, Stroobants S, Verhoef G, Balzarini J, et al. Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET. Eur J Nucl Med Mol Imaging. 2010;37(9):1688-95.
25. Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27(2):235-8.
26. Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, et al; Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12(5):460-8.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
28. Hurley LH. DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer. 2002;2:188-200.
29. Greiner DL, Hesselton RA, Shultz LD. SCID mouse models of human stem cell engraftment. Stem Cells. 1998;16(3):166-77.
30. Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, et al. [(18)F]FDG-PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging. 2003;30(5):682-8.
31. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33(11):1972-80.
32. Brepoels L, Stroobants S, Verhoef G, De Groot T, Mortelmans L, et al. (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model. J Nucl Med. 2009;50(7):1102-9.
33. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D- glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med. 1993;34(5):773-9.
34. Aloj L, Caracó C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res. 1999;59(18):4709-14.
35. Haberkorn U, Morr I, Oberdorfer F, Bellemann ME, Blatter J, Altmann A, et al. Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine. J Nucl Med. 1994;35(11):1842-50.
36. Jensen MM, Jørgensen JT, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging. 2008;8:16.
37. Jensen MM, Erichsen KD, Björkling F, Madsen J, Jensen PB, et al. Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG-PET in human ovary cancer xenografts in mice. PLoS One. 2010;5(9):e12965.
38. Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, et al. Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy- 3′-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res. 2006;12:4590-7.
39. Herrmann K, Buck AK, Schuster T, Rudelius M, Wester HJ, et al. A pilot study to evaluate 3′-deoxy-3′-18F-fluorothymidine PET for initial and early response imaging in mantle cell lymphoma. J Nucl Med. 2011;52(12):1898-902.
40. Herrmann K, Buck AK, Schuster T, Junger A, Wieder HA, et al. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med. 2011;52(5):690-6.
41. Troost EG, Vogel WV, Merkx MA, Slootweg PJ, Marres HA, et al. 18F-FLT-PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726-35.
42. Wieder HA, Geinitz H, Rosenberg R, Lordick F, Becker K, et al. PET imaging with [(18)F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:878-83.